Severe early-childhood-onset retinal dystrophy
MONDO:0009549Severe early childhood onset retinal dystrophy (SECORD) is an inherited retinal dystrophy, characterized by a severe congenital night blindness, progressive retinal dystrophy and nystagmus. Best corrected visual acuity can reach 0.3 in the first decade of life and can pertain well into the second decade of life. Blindness is often complete by the age of 30 years. An overlap with Leber congenital amaurosis (LCA) occurs when patients are characterized by their visual acuity and panretinal dystrophy.
Also known as: EOSRD, SECORD, Stargardt disease type 1, early-onset severe retinal dystrophy, STGD1, Stargardt disease 1, Stgd, fundus flavimaculatus
37 clinical trials for this condition and its sub-types, 10 tagged with Severe early-childhood-onset retinal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Promising drug may slow blindness in teens with rare eye disease
Disease control CompletedThis study tested an experimental drug called tinlarebant in 104 teenagers with Stargardt disease, a genetic condition that causes progressive vision loss. The goal was to see if the drug could slow the growth of damage in the back of the eye. Participants took the drug or a plac…
Phase 3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug aims to slow vision loss in rare eye disease
Disease control CompletedThis study tested an experimental drug called Zimura in 121 people with Stargardt disease, a genetic condition that causes vision loss. Participants received either Zimura injections or a sham procedure. The goal was to see if Zimura could safely slow damage to the retina over 18…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC